MitraClip for the Treatment of Moderate Functional Mitral Regurgitation: EVOLVE-MR
Launched by MONTREAL HEART INSTITUTE · Oct 11, 2018
Trial Information
Current as of June 20, 2025
Unknown status
Keywords
ClinConnect Summary
Moderate mitral regurgitation in patients with LV dysfunction is associated with increased risk of death and hospitalizations for heart failure (HF) and leads to progressive remodelling of an already damaged left ventricle. Medical therapies and cardiac resynchronization therapy (CRT) have demonstrated favourable effects on LV remodelling in heart failure patients.
Given the benefits and safety of transcatheter mitral valve repair with the MitraClip device in severe MR, it is conceivable that this technology could also be safely used in those with moderate MR to reduce mitral regurgitation...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Moderate functional mitral regurgitation (2+, 2-3+)
- • Left ventricular ejection fraction \>20%
- • LVEDV 75-110 ml/m2
- • Symptomatic heart failure (NYHA Class II-IV)
- Exclusion Criteria:
- • Left ventricular ejection fraction \< 20%
- • Severe functional mitral regurgitation
- • Recent coronary artery bypass graft surgery (CABG)
- • Untreated significant coronary artery disease
- • Mitral valve area \< 4.0cm2
- • Severe pulmonary hypertension
About Montreal Heart Institute
The Montreal Heart Institute (MHI) is a leading academic research center dedicated to advancing the field of cardiology through innovative clinical trials and groundbreaking medical research. Renowned for its commitment to improving patient care, MHI integrates clinical practice with cutting-edge research, fostering collaboration among healthcare professionals, scientists, and industry partners. The institute focuses on a wide range of cardiovascular conditions, aiming to develop and evaluate new therapies and interventions that enhance outcomes for patients with heart disease. With a strong emphasis on ethical standards and patient safety, the Montreal Heart Institute is at the forefront of cardiovascular research, contributing significantly to the global advancement of heart health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, Quebec, Canada
Patients applied
Trial Officials
Anita W Asgar, MD
Principal Investigator
Montreal Heart Institute
Anique Ducharme, MD
Principal Investigator
Montreal Heart Institute
Jean L Rouleau, MD
Study Chair
Montreal Heart Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials